Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 3,916 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Bridgeport, Connecticut • Derby, Connecticut • Greenwich, Connecticut + 3 more

Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions: Not listed
Lead sponsor: Adela, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel; Combination Product · Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 26
States / cities: Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more

Conditions: Prostate Cancer
Interventions: Prostatectomy; Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cancer
Interventions: HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel; Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Scottsdale, Arizona • Boston, Massachusetts

Conditions: Fatigue, Prostate Cancer
Interventions: Ritalin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
Interventions: YM155; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 7
States / cities: Tuscon, Arizona • Los Angeles, California • Coeur d'Alene, Idaho + 4 more

Conditions: Prostate Cancer
Interventions: Health promotion; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan + 1 more

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Prostate Cancer Clinical Trials Consortium; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2037
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Seattle, Washington

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Sunphenon, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Westwood, Kansas

Conditions: Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, Sargramostim; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 7
States / cities: Jacksonville, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more

Conditions: Recurrent Prostate Cancer
Interventions: Adenovirus/PSA Vaccine; Biological
Lead sponsor: David M Lubaroff; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
Interventions: cabozantinib, abiraterone, prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 20
States / cities: Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more

Conditions: Prostate Cancer, Elevated PSA
Interventions: prostate biopsy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: pomegranate extract, pomegranate juice, placebo; Dietary Supplement
Lead sponsor: Roll International Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: SpaceIT Hydrogel System, Commercially available Boston Scientific Spacer; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Laguna Hills, California • Los Angeles, California • Miami, Florida + 18 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate; Procedure · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Prednisone; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Advanced Cancer
Interventions: Brief FOCUS Program, Extensive FOCUS Program; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Southfield, Michigan

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: DCVAC/PCa, Placebo; Biological
Lead sponsor: SOTIO a.s.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 58
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more

Conditions: Prostate Cancer
Interventions: Unilateral Nerve-Sparing Cryoablation of the Prostate, Precise Cryoablation System with IceRod Needles; Procedure · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 69 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Prostate Cancer
Interventions: BMS-986218 and Degarelix, Degarelix; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Guided Biopsy for Mapping Prostate Cancer

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Psychostimulants for Fatigue in Prostate Cancer

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches

Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer

SpaceIT Hydrogel System for Perirectal Spacing

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Outcomes of Triaged Family Care in Advanced Cancer

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer